Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Extavia was a U.S. interferon beta-1b product for subcutaneous injection. Its final U.S. prescribing information indicated treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. FDA currently lists Extavia as discontinued in the Purple Book.
read more about what was extavia ...The mechanism by which interferon beta-1b produces its effects in multiple sclerosis is not known. Interferon beta-1b has immunomodulatory activity and changes biologic responses after binding to interferon receptors on human cells. The clinical effect was a reduction in disease activity in relapsing forms of multiple sclerosis.
The final U.S. indication covered adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis. Safety and efficacy in pediatric patients were not established in the U.S. prescribing information.
Treatment started at 0.0625 mg subcutaneously every other day for weeks 1 and 2. The dose increased to 0.125 mg every other day for weeks 3 and 4, then 0.1875 mg every other day for weeks 5 and 6. From week 7 onward, the recommended dose was 0.25 mg every other day.
Serious concerns included liver injury and liver failure, depression and suicidal thoughts or behavior, anaphylaxis, injection-site necrosis, worsening heart failure, reduced blood-cell counts, thrombotic microangiopathy, pulmonary arterial hypertension, and drug-induced lupus. Laboratory monitoring included liver enzymes and blood-cell counts during treatment.
Extavia was indicated for relapsing forms of multiple sclerosis in adults.
No. FDA currently lists Extavia as discontinued.
The recommended maintenance dose was 0.25 mg by subcutaneous injection every other day.
Yes. The dose increased stepwise over six weeks before reaching the maintenance dose in week 7.
Beta Interferon. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548080/. Date Accessed September 30, 2026.
DailyMed - EXTAVIA (interferon beta-1b) for injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4cfdb571-ec4c-478f-bedc-e0669eeea504. Date Accessed September 30, 2026.
Interferon Beta-1B. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Interferon-Beta-1B. Date Accessed September 30, 2026.
Interferon Beta-1b Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a601151.html. Date Accessed September 30, 2026.
Purple Book Search - Extavia. U.S. Food and Drug Administration. https://purplebooksearch.fda.gov/index.cfm?blaNo=125290&event=productdetails. Date Accessed September 30, 2026.